Drugs / NKG2D-based CAR T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05131763 | Mar 2021 → Dec 2022 | colon carcinoma, glioblastoma, hepatocellular carcinoma, medulloblastoma | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT04270461 | Mar → Oct 2020 | colon carcinoma, glioblastoma, hepatocellular carcinoma, medulloblastoma | Jiujiang University Affiliated Hospital | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D-based CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270461 ↗ |
| Action | Deplete | “NKG2D-based CAR-T cells showed strong cytotoxicity against NKG2DL+ cell lines in vitro” NCT04270461 ↗ |
| Modality | Cell therapy | “NKG2D-based CAR-T represent a potentially effective and safety therapeutic approach” NCT04270461 ↗ |
| Route | Intravenous | “administered by i.v.” NCT04270461 ↗ |